Amlodipine
This calcium channel blocker relaxes the walls of blood vessels, making it easier for the heart to pump blood and lowering blood pressure. It is prescribed for hypertension and chest pain, and some research suggests potential roles in neurological and heart rhythm conditions.
Masse moléculaire
408,8800 g/mol
LogP
3,00
TPSA
99,90 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Classes de médicaments
Mécanisme d'action
Dihydropyridine calcium channel blocker.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Dihydropyridine calcium channel blocker.
Structure 2D
Cite this structure
Embed this structure
SMILES
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl
InChI
InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3
Molecular Formula
C20H25ClN2O5
HBD / HBA
2 / 7
Liaisons Rotatives
10
Atomes Lourds
28
The combination of amlodipine and lisinopril provides complementary antihypertensive mechanisms and may cause additive hypotension, particularly with initial dosing.
Amlodipine weakly inhibits CYP3A4-mediated atorvastatin metabolism, leading to a modest increase in atorvastatin exposure; the combination is generally used safely in clinical practice.
Doxycycline is reported to modestly inhibit CYP3A4, potentially increasing amlodipine plasma levels; the clinical consequence is minor given amlodipine's wide therapeutic index.
Amlodipine inhibits CYP3A4-mediated simvastatin metabolism, increasing simvastatin plasma concentrations and the risk of statin-associated myopathy and rhabdomyolysis.
Cyclosporine inhibits CYP3A4-mediated amlodipine metabolism, increasing amlodipine plasma concentrations and the risk of pronounced vasodilation and peripheral edema.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
This calcium channel blocker relaxes the walls of blood vessels, making it easier for the heart to pump blood and lowering blood pressure. It is prescribed for hypertension and chest pain, and some research suggests potential roles in neurological and heart rhythm conditions.
Dihydropyridine calcium channel blocker.
Key pharmacokinetic parameters for Amlodipine: Half-life: 30-50 hours.
Yes, Amlodipine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1491. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2162. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="amlodipine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/amlodipine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/amlodipine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/amlodipine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="amlodipine"></drugfyi-drug>